- Short description
The webinar addresses the complexity of the treatment of challenging cases of APS, and in particular catastrophic antiphospholipid syndrome. What can we do beyond anticoagulation? Primary and secondary thromboprophylaxis in Antiphospholipid syndrome based on evidence-based recommendations are also explored. .
APS is a systemic autoimmune disease with the highest prevalence in women of childbearing age, characterized by venous and/or arterial thrombosis, pregnancy complications and the presence of specific autoantibodies called antiphospholipid antibodies (aPL).
All resources and more info on APS can be found here: reconnet.ern-net.eu/disease-aps/
Speakers
- Prof. Savino Sciascia, HUB S. Giovanni Bosco, Torino (Italy) is a Consultant at the Multidisciplinary Centre for Immunopathology and Rare Diseases, University di Torino, Italy. His major research interests include the management of patients with autoimmune conditions, with a specific focus on Systemic Lupus Erythematosus, and antiphospholipid antibodies syndrome. He received his MD cum laude from the University of Turin Medical School. He earned his PhD in Complex Systems for Life Sciences investigating mathematic models for risk assessment in patients with autoimmune diseases in collaboration with the Lupus Unit, Guy's and St Thomas' Hospital, King’s College, London, UK.
- Dr. Luca Moroni, IRCCS Ospedale San Raffaele, Milano (Italy). He graduated in Medicine in 2011 at the University of Milan and later obtained a specialization degree in Internal Medicine in 2017; in 2018, he earned a Master of Science at University of Barcelona on Systemic Autoimmune Diseases. Currently, he works at San Raffaele Hospital (Milan) in the Immunology and Rheumatology Unit, in particular he is investigating Systemic Lupus Erythematosus, Antiphospholipid Syndrome, Sjogren Syndrome, Small Vessel Vasculitides, and Behcet Disease.
- Moderator
Prof. Maria Tektonidou is Professor of Rheumatology, Head of Rheumatology Unit, and Head of the National Center of Expertise for Rare and Complex Connective Tissue and Musculoskeletal Diseases at the First Department of Propaedeutic Internal Medicine, University of Athens, Greece. She is Executive board member of the Joint Academic Rheumatology program, University of Athens, “EULAR Centre of Excellence”. She is leading the “EULAR Antiphospholipid syndrome study group” and she convened the “EULAR Recommendations for the management of APS in adults”, the “EULAR recommendations for the cardiovascular management of RMDs including SLE and APS”, and she is currently convening the "Development and Validation of a EULAR disease activity score in APS" project. She is steering committee member of the “ACR/EULAR Classification Criteria for APS”. She is disease coordinator of the ERN ReCoNNET APS group, a steering committee member of the ‘AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION), and executive committee member of the “European Lupus Society-SLEuro".
Негізгі бет How we treat challenging cases of Antiphospholipid syndrome (APS)
Пікірлер: 3